Serum procalcitonin levels can be used to differentiate between inflammatory and non-inflammatory diarrhea in acute infectious diarrhea

Hae Jin Shin, MD, Sun Hyung Kang, MD, PhD, Hee Seok Moon, MD, PhD, Jae Kyu Sung, MD, PhD, Hyun Yong Jeong, MD, PhD, Ju Seok Kim, MD, Jong Seok Joo, MD, Eum Seok Lee, MD, PhD, Seok Hyun Kim, MD, PhD, Byung Seok Lee, MD, PhD

Abstract
In this study, we assess the possibility of using procalcitonin levels to differentiate between inflammatory diarrhea and non-inflammatory diarrhea in acute infectious diarrhea. We reviewed the records of 1176 patients who had symptoms of diarrhea, fever (≥37.8°C), and abdominal pain between March 2011 and May 2015. After applying exclusion criteria, a sample of 514 patients was considered for study. The patient sample was divided into Group A and Group B for inflammatory diarrhea and non-inflammatory diarrhea, respectively. The assessment involved comparing the laboratory characteristics with the clinical characteristics of the groups.

The characteristics of Group A, such as white blood cell (WBC), C-reactive protein (CRP), absolute neutrophil count (ANC), and procalcitonin levels, were relatively higher than those of Group B (P < .001 for Group A). A receiver operator characteristic (ROC) analysis revealed that the highest area-under-the-curve (AUC) value of procalcitonin (0.797; 95% confidence interval [CI] [0.760, 0.831]; P < .001), could be used to differentiate between the 2 groups. Procalcitonin exhibited a sensitivity and a specificity of 87.03% and 68.75%, respectively, at a 0.08 ng/mL cut-off level.

Procalcitonin was a good candidate biomarker of inflammatory diarrhea than other inflammatory markers.

Abbreviations: ANC = absolute neutrophil count, AUC = area-under-the-curve, CI = confidence interval, CRP = C-reactive protein, CT = computed tomography, EIEC = enteroinvasive Escherichia coli, FOBT = fecal occult blood test, OR = odds ratio, ROC = receiver operator characteristic, SPSS = Statistical Package for the Social Sciences, STEC = shiga toxin-producing E.coli, WBC = white blood cell.

Keywords: acute infectious diarrhea, inflammatory diarrhea, non-inflammatory diarrhea, procalcitonin

1. Introduction
From a global perspective, infectious diarrhea is one of the most common diseases, predominantly among the developing nations. The fatality level associated with infectious diarrhea has remained high despite enhanced hygiene and treatment. Acute infectious diarrhea can be categorized as inflammatory (cytotoxin or invasion) and non-inflammatory (enterotoxin). Enterotoxin causes watery diarrhea by acting directly on secretory mechanisms in the intestinal mucosa, while cytotoxin or bacterial invasion cause destruction of mucosal cells and associated inflammatory diarrhea. The wide range of clinical manifestations of acute infectious diarrhea is matched by the wide variety of infectious agents involved, including viruses, bacteria, and parasites. A significant number of non-inflammatory cases of diarrhea are caused by viruses, parasites, and a range of bacteria, with the common treatment being oral hydration and proper nutrition. Inflammatory diarrhea results from invasive pathogens, such as Entamoeba histolytica, enteroinvasive Escherichia coli (EIEC), Shigella, shiga toxin-producing E.coli (STEC), Salmonella, and Campylobacter, and is related to immense inflammation in the intestines; a distinctive diagnosis is essential to determine the necessary antimicrobial therapy. This indicates why it is compulsory to distinguish non-inflammatory diarrhea from inflammatory diarrhea upon a patient’s admission.

Despite the fact that stool culture remains the primary technique employed in differentiating non-inflammatory from inflammatory diarrhea, it is very costly. Furthermore, about 80% of samples cannot be determined using stool culture, and professionals and high-tech equipment are needed to analyze stools.

The rapid stool examination requiring a microscopic assessment for erythrocytes and leukocytes has limited value for distinguishing between pathogens in watery diarrhea. Both the lactoferrin latex agglutination test and the fecal occult blood test (FOBT) are simple, quick, and cost-effective tests that can be used to screen for inflammatory diarrhea. However, these tests
require modern laboratories with competent technicians, and they have a low specificity and sensitivity. An increased level of procalcitonin is considered a key laboratory indication of acute infection, and it has been confirmed as a marker of bacterial infection among intensive care unit and post-surgical patients, as well as neonatal sepsis patients. As an inactive calcitonin precursor, procalcitonin is a 116-amino acid polypeptide glycoprotein with a 13 kDa molecular weight. Serum concentrations in healthy persons are very low, <0.05 ng/mL, or sometimes even undetectable. Increased levels of procalcitonin were initially reported by French authors in patients with sepsis, as well as fungal and bacterial infections. Some of the benefits associated with using procalcitonin as an inflammatory marker is that it is a simple and reliable test that has a quick turnaround time of 2 hours for the results. From a general assessment and meta-analysis perspective, procalcitonin performed better than C-reactive protein (CRP) as a biomarker in relation to the diagnostic precision of bacterial infection among inpatients. The function of procalcitonin in the diagnosis of necrotizing pancreatitis, in the discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome, and in surveying infection in transplant recipients has been studied. There have also been confirmed reports concerning the correlation of procalcitonin with disease activity in a range of autoimmune settings, such as the Wegener granulomatous disease.

The objective of the present study centered on examining the efficacy of inflammatory markers, particularly procalcitonin, in the discrimination between inflammatory and non-inflammatory diarrhea in patients with acute infectious diarrhea. The study also examined the significance of such infection markers during antibiotic therapy, since the antibiotic therapy for gastroenteritis is considered highly controversial among stable patients. Avoiding needless antibiotic therapy in healthcare facilities is a top concern among professionals in this sector because of antibiotic resistance and allergic reactions.

2. Materials and methods

2.1. Study population and design

This study employed a retrospective methodology based on data from a tertiary hospital in Daejeon, Republic of Korea. We reviewed the records of 1176 patients who presented at the hospital with symptoms of diarrhea, fever (≥37.8°C), and abdominal pain between March 2011 and May 2015. The eligibility criteria involved undergoing a colonoscopy or abdominal computed tomography (CT) within the first 3 days of being admitted, as well as sampling blood during admission. The patients were subdivided into Group A and Group B for inflammatory diarrhea and non-inflammatory diarrhea, respectively.

The assessment involved comparing the laboratory characteristics with the clinical characteristics of the 2 groups. For Group A, the inflammatory diarrhea group, patients had the following conditions: bowel wall thickening >5 mm, pericolonic stranding or fluid collection at the distal ileum or colon on abdominal CT; and hemorrhage, erythema, edema, or ulcer on colonoscopy. For Group B, the group with non-inflammatory diarrhea, the patients did not show abnormal findings during a colonoscopy or abdominal CT. The exclusion criteria involved patients with inflammatory bowel disease, intestinal tuberculosis, or diverticulitis, patients who had taken antibiotics prior to admission, and patients who did not check abdominal CT, colonoscopy, and serum procalcitonin. From the 1176 records of patients examined, 662 patients were excluded, while 514 patients were included in the study (Fig. 1). For this retrospective study, written informed consent was not required.

2.2. Statistical analysis

The statistical software used in analyzing the collected data was SPSS software, version 12.0 (SPSS, Chicago, IL). Categorical data were analyzed with chi-squared statistics or Fisher exact test. Continuous data were analyzed using a t test. To establish the independent indicators of inflammatory diarrhea, we performed
**3. Results**

From the 514 patients who were considered eligible for this study, 72% (n = 370) were included in the inflammatory diarrhea group (Group A), while the remaining 28% (n = 144) were included in the non-inflammatory diarrhea group (Group B). Tables 1 and 2 present the baseline clinical characteristics and the laboratory characteristics of the 2 groups.

The results did not reveal any significant clinical variations between the 2 groups. From the laboratory tests, it was evident that the white blood cell (WBC) count, the absolute neutrophil count (ANC), and the CRP and procalcitonin levels were statistically higher in Group A (P < .001) compared with Group B. The analysis of a multivariate logistic regression showed that the noteworthy independent predictors for inflammatory diarrhea were CRP and procalcitonin levels (Table 3).

The level of procalcitonin was the main determinant of inflammatory diarrhea (odds ratio [OR] 1.321, P < .001). Procalcitonin had a high value of area-under-the-curve (AUC) of 0.797 (95% confidence interval [CI] [0.760, 0.831]; P < .001) within the ROC diagnosis to differentiate non-inflammatory from inflammatory diarrhea (Table 4 and Fig. 2). In the inflammatory diarrhea analysis, procalcitonin had a sensitivity of 87.03% and a specificity of 68.75% at a cut-off level of 0.08 ng/mL. CRP also had a comparatively high AUC value of 0.697 (95% CI [0.636, 0.737]; P < .001), although its sensitivity (81.08%) and specificity (51.39%) were less than procalcitonin.

### 4. Discussion

As confirmed in our study, clinical symptoms cannot be used to dependably differentiate non-inflammatory diarrhea from inflammatory diarrhea in patients with acute infectious diarrhea. In this retrospective study, we separated patients with acute infectious diarrhea into 2 groups, non-inflammatory and inflammatory diarrhea, based on the results from an abdominal CT or colonoscopy. We compared the clinical characteristics of the 2 groups and explored the aptitude of various inflammatory indicators in differentiating between them. We found that the procalcitonin levels in patients with acute infectious diarrhea could help clinicians differentiate between non-inflammatory and inflammatory diarrhea. Currently, little research has been done on the precision of using procalcitonin to differentiate between non-inflammatory and inflammatory diarrhea. In our study, which involved 514 patients, we demonstrated that the determination of serum procalcitonin could have significant predictive value (OR 1.321, AUC 0.797) for the analysis of inflammatory diarrhea, and offered a better predictive value compared with CRP (OR 1.145, AUC 0.697). In the inflammatory diarrhea analysis, procalcitonin had a sensitivity of 87.03% and a specificity of 68.75% at a cut-off level of 0.08 ng/mL.

---

**Table 1**

Baseline clinical characteristics of the study cohort.

| Characteristics         | Group A (n = 370) | Group B (n = 144) | P value |
|-------------------------|------------------|------------------|---------|
| Age, y                  | 63.76 ± 0.80     | 62.28 ± 1.33     | < .001  |
| Men, n (%)              | 228 (61.6%)      | 76 (52.8%)       | < .001  |
| Hypertension, n (%)     | 105 (28.4%)      | 83 (57.6%)       | < .001  |
| Diabetes, n (%)         | 103 (28.2%)      | 35 (24.3%)       | < .001  |

**Table 2**

Baseline laboratory results for the study cohort.

| Characteristics         | Group A (n = 370) | Group B (n = 144) | P value |
|-------------------------|------------------|------------------|---------|
| WBC (×10^3/µL)          | 11.05 ± 3.30     | 8.76 ± 0.29      | < .001  |
| ANC (×10^3/µL)          | 9.19 ± 0.26      | 6.64 ± 0.27      | < .001  |
| AST, IU/L               | 36.8 ± 3.46      | 45.4 ± 6.04      | < .001  |
| ALT, IU/L               | 29.8 ± 3.27      | 38.4 ± 6.00      | < .001  |
| BUN, mg/dl              | 19.1 ± 0.65      | 16.21 ± 1.10     | < .001  |
| Creatinine, mg/dl       | 1.16 ± 0.06      | 1.04 ± 0.10      | < .001  |
| CRP, mg/dl              | 5.52 ± 0.23      | 3.06 ± 0.31      | < .001  |
| Procalcitonin, ng/mL    | 0.24 ± 0.17      | 0.58 ± 0.12      | < .001  |
| Positive for fecal WBC, n (%) | 124 (35.5%) | 8 (11.1%) | < .001 |
| Positive for FOBT, n (%) | 54 (24.1%) | 5 (6.9%) | < .001 |

**Table 3**

Multivariate analysis of possible risk factors for inflammatory diarrhea.

| Characteristics      | Odds ratio | 95% CI     | P value |
|----------------------|------------|------------|---------|
| WBC                  | 0.873      | 0.073-1.043| < .001  |
| ANC                  | 1.293      | 1.046-1.508| < .001  |
| CRP                  | 1.145      | 1.075-1.220| < .001  |
| Procalcitonin        | 1.321      | 1.153-1.514| < .001  |

**Table 4**

ROC analysis to differentiate inflammatory from non-inflammatory diarrhea with diverse serum indicators of infection.

| Characteristics      | AUC Cut-off level | Sensitivity (%) | Specificity (%) |
|----------------------|-------------------|-----------------|-----------------|
| WBC                  | > 0.62            | 39.73           | 84.03           |
| ANC                  | > 0.56            | 80.54           | 47.92           |
| CRP                  | > 0.67            | 81.08           | 51.39           |
| Procalcitonin        | > 0.79            | 87.03           | 68.75           |

**Note:**

ALT = alanine transaminase, ANC = absolute neutrophil count, AST = aspartate transaminase, BUN = blood urea nitrogen, CRP = C-reactive protein, FOBT = fecal occult blood test, WBC = white blood cells.

---
There are 2 studies about the usefulness of measuring procalcitonin levels from a prospective setting. In a study performed by Herrlinger et al.,[21] patients with self-limited enterocolitis showed significantly higher procalcitonin levels when compared with inflammatory bowel disease patients (0.36 ng/mL, 95% CI [0.18, 1.7] vs 0.10 ng/mL, 95% CI [0.08, 0.5]; P < .001). Using the cut-off level procalcitonin ≥0.4 ng/mL, the sensitivity for self-limited colitis was 92% and the specificity was 96%. The positive predictive value for self-limited colitis was 96%, whereas the negative predictive value was 93%. Thia et al.[22] evaluated the utility of procalcitonin in diagnosing gastroenteritis. Using the cut-off level procalcitonin ≥0.5 ng/mL, the sensitivity for bacterial gastroenteritis was 40% and the specificity was 92%. When a lower procalcitonin ≥0.1 ng/mL cut-off level was chosen, the sensitivity was higher (93%) but the specificity was reduced to 50%. Based on the AUC for the ROC curve, procalcitonin performed well in the prediction of bacterial gastroenteritis, with an AUC of 0.727 (95% CI [0.580, 0.874]; P = .006).

In the observational studies, the probability of bacterial infection was defined as very unlikely (<0.1 ng/mL), unlikely (0.1–0.25 ng/mL), likely (0.25–0.5 ng/mL), and very likely (>0.5 ng/mL) according to the cut-off levels of procalcitonin. The use of antibiotics was recommended when the procalcitonin level was >0.25 ng/mL, while avoiding the use of unnecessary antibiotics when the procalcitonin level was lower than 0.25 ng/mL.[23] Some authors have shown the importance and role of procalcitonin in randomized controlled trials rather than observational studies.[24,25] Ismaili-Jaha et al.[26] classified the etiology of diarrhea according to the cut-off levels of procalcitonin in patients with diarrhea. First, the mean and peak values of procalcitonin in patients with diarrhea due to viral infection were 0.133 and 2.30 ng/mL, respectively. Second, the mean and peak values of procalcitonin in patients with diarrhea due to bacterial infection were 5.30 and 18.0 ng/mL, respectively. Finally, the mean and peak values of procalcitonin in patients with extra-intestinal diarrhea (sepsis, meningitis) were 1.638 and 12.40 ng/mL, respectively.

The main method of detecting bacterial infection is through culture. Examinations to identify viral infections involve acute and convalescent-stage antibody titers and trials for viral antigens. However, outcomes using these methods can be delayed, while fast immunological or genomic assessments require information about the infectious agent. Early detection of bacterial infections could potentially direct management and decrease the abuse of antibiotics, causing enhanced long-term outcomes.[27] Among numerous indicators of inflammation and sepsis, procalcitonin, an acute-stage reactant, has been researched for its capability to precisely detect bacterial infection.

During systemic inflammation, specifically in bacterial infections, under the impact of inflammatory cytokines and bacterial endotoxins, procalcitonin, which is synthesized in several tissues, such as the lung, kidney, liver, and adipose tissue, enters the circulatory system. At this stage, the level of procalcitonin can increase up to 1000 times that of the original level.[28,29] The initial detectable values of procalcitonin are established 2 to 4 hours following stimulation; the highest levels of procalcitonin are reached within 6 to 24 hours.[28,29] In contrast, the CRP level increases 12 to 24 hours following stimulation, attaining the highest level after 48 hours.[28] The concentration of procalcitonin is not influenced by neutropenia, immunodeficiency circumstances, or the use of nonsteroidal and steroidal anti-inflammatory treatments, which is not the situation with CRP.[30] As an increase in the level of procalcitonin corresponds to the intensity of the inflammatory response and the severity of the infection, thus, increased concentrations or continuously high levels can be prognostic markers for severe types of infection with adverse outcomes.[31] Based on the technique of measurement used, the procalcitonin level within a patient’s blood can be measured within a range of 19 minutes to 2.5 hours.[28,29] Circulating procalcitonin level is halved in 24 hours after treatment of the infection, either by the immune system or by an antibiotic,[32] which makes it an indicator of the usefulness of the treatment. In addition, studies have demonstrated that the addition of procalcitonin in treatment guidelines decreases the use of antibiotics without adverse consequences affecting the final outcome of the infection.[31,34]

The American College of Gastroenterology recommends the use of empirical antibiotic therapy in adult gastroenteritis patients with acute infectious diarrhea.[33] Therefore, it is essential to recognize patients that have acute infectious diarrhea caused by bacteria. Thia et al.[22] found that detecting the level of procalcitonin helped in the discrimination of bacterial and undifferentiated gastroenteritis. However, they used stool cultures that were not sensitive enough to diagnose bacterial gastroenteritis. Our study employed much more sensitive means (colonoscopy and imaging research). Moreover, our study included a larger study population compared with that of Thia et al.

There are 2 new knowledges from this study. First, this is the rare study of serum procalcitonin levels in differentiating between inflammatory and non-inflammatory diarrhea in patients with acute infectious diarrhea. Currently, to our knowledge, there are very few reports about the usefulness of serum procalcitonin in acute infectious diarrhea. Second, in the inflammatory diarrhea analysis, procalcitonin showed superior sensitivity and specificity compared with CRP. The serum procalcitonin levels can be measured quickly and it helps to make an early diagnosis in an
Emergent situation such as systemic inflammation or septic shock. Inflammatory diarrhea can have serious complications if not treated with antibiotics especially in old age and immunocompromised patients. On the other hand, treating non-inflammatory diarrhea with antibiotics is not only unsuccessful, but also increases antibiotic resistance, costs of treatment, and toxicity of drug and allergic reactions. Therefore, the level of procalcitonin in a patient with acute infectious diarrhea on admission might assist with clinician's decision-making, such as whether to begin empirical antibiotic treatment.

However, our study has some limitations. First, it was a retrospective study. This means that, the patient information might be inaccurate. Second, since all patients with acute infectious diarrhea included in this study were diagnosed and treated at our single center, there are restrictions regarding general representability because of a relatively small sample size. Third, inflammatory and non-inflammatory diarrhea patients were differentiated by colonoscopy and imaging research; no microscopic stool examinations or stool cultures were conducted. Fourth, we only measured procalcitonin levels on admission, and did not follow procalcitonin levels, because we wanted to see if a single measurement on admission can differentiate between inflammatory and non-inflammatory diarrhea. Fifth, there were insufficient investigations of other co-morbidities except hypertension and diabetes. Patients with cancer or another immunocompromised disease are more susceptible to infection and may have higher procalcitonin levels. Finally, it is a relatively low specificity value of procalcitonin. Because the medical insurance cost of national health insurance corporation is relatively low, a test and lactoferrin latex agglutination test in screening hospitalized patients for diagnosing inflammatory and noninflammatory diarrhea in Dhaka, Bangladesh. Digestion 2007;76:256–61.

Le Moullec JM, Julienne A, Chenas J, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984;167:95–7.

Whicher J, Bievenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001;38:483–95.

Suberviola B, Castellanos-Ortega A, Gonzalez-Castro A, et al. Prognostic value of procalcitonin, C-reactive protein and leukocytes in septic shock. Med Intensiva 2012;36:177–84.

Assessor M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:513–8.

Engius A, Rey C, Concha A, et al. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001;27:211–5.

Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206–17.

Rau B, Steinbach G, Gansauge F, et al. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997;41:832–40.

Bunckhorst OM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 1999;27:2172–6.

Kuse ER, Langelid J, Jaeger K, et al. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 2000;28:555–9.

Moosig F, Cernok E, Reinhold-Keller E, et al. Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol 1998;25:1531–3.

Lubasch A, Lode H. The role of antibiotic therapy in infectious enteritis. Internist (Berl) 2000;41:494–7.

Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect 2009;15:12–5.

Desai RK, Taglabue JR, Wegrzy SA, et al. CT evaluation of wall thickening in the alimentary tract. Radiographics 1991;11:771–83.

Herrlinger KR, Dittmann R, Weitz G, et al. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 2004;10:229–33.

Tha KT, Chan ES, Ling KL, et al. Role of procalcitonin in infectious gastroenteritis and inflammatory bowel disease. Dig Dis Sci 2008;53:2960–8.

Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14:203.

Schurtz P, Albirich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011;9:107.

Schurtz P, Albirich W, Christ-Crain M, et al. Procalcitonin for guidance of antibiotic therapy. Expert Rev Antic Infec Ther 2010;8:575–87.
[26] Ismaili-Jaha V, Shala M, Azemi M, et al. Sensitivity and specificity of procalcitonin to determine etiology of diarrhea in children younger than 5 years. Mater Sociomed 2014;26:76–9.
[27] Velicer CM, Heckbert SR, Lampe JW, et al. Antibiotic use in relation to the risk of breast cancer. JAMA 2004;291:827–35.
[28] Mehenic S, Baljic R. The importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsis. Mater Sociomed 2013;25:277–81.
[29] Chan T, Gu F. Early diagnosis of sepsis using serum biomarkers. Expert Rev Mol Diagn 2011;11:487–96.
[30] Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections – hope for hype? Swiss Med Wkly 2009;139:318–26.
[31] Karlsson S, Heikkinen M, Pettala V, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010;14:R205.
[32] Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322–31.
[33] Bouadma L, Luyt C, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463–74.
[34] Albrich CW, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715–22.
[35] DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997;92:1962–75.